BAYTRIL 50 MG/ML SOLUTION FOR INJECTION

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

ENROFLOXACIN

Inapatikana kutoka:

Bayer Limited

ATC kanuni:

QJ01MA90

INN (Jina la Kimataifa):

ENROFLOXACIN

Kipimo:

50 Mg/Ml

Dawa fomu:

Solution for Injection

Dawa ya aina:

POM

Kundi la matibabu:

Bovine, Canine, Caprine, Feline, Ovine, Porcine

Eneo la matibabu:

Enrofloxacin

Matibabu dalili:

Antibacterial

Idhini hali ya:

Authorised

Idhini ya tarehe:

1988-10-01

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baytril 50 mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml solution contains:
ACTIVE SUBSTANCE:
Enrofloxacin: 50 mg
EXCIPIENT(S):
n-Butyl alcohol: 30 mg.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear light yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (calves), sheep, goats, pigs, dogs and cats.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Calves
Treatment of infections of the respiratory tract caused by
enrofloxacin susceptible strains of_ Pasteurella multocida,_
_Mannheimia haemolytica_ and_ Mycoplasma_ spp.
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of_ Escherichia coli._
Treatment of septicaemia caused by enrofloxacin susceptible strains
of_ Escherichia coli._
Treatment of acute mycoplasma-associated arthritis due to enrofloxacin
susceptible strains of_ Mycoplasma bovis._
Sheep
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of_ Escherichia coli._
Treatment of septicaemia caused by enrofloxacin susceptible strains
of_ Escherichia coli._
Treatment of mastitis caused by enrofloxacin susceptible strains of_
Staphylo